Try our Advanced Search for more refined results
GlaxoSmithKline LLC et al v. Teva Pharmaceuticals USA Inc.
Case Number:
1:14-cv-00878
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 11, 2024
GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals
A GlaxoSmithKline lawyer has urged a Delaware federal judge to make up his mind about a nearly $400 million patent case against Teva Pharmaceuticals in light of unrelated "opioid-related cases" that the Israeli generic-drug maker has been settling in the billions of dollars.
-
March 28, 2018
Teva Skirts $235M Infringement Verdict In Coreg Patent Row
A Delaware federal judge on Wednesday released Teva Pharmaceutical Industries Ltd. from a $235 million verdict over its generic version of GlaxoSmithKline LLC's heart medication Coreg, finding Teva did not infringe a patent covering the drug.
-
October 26, 2017
GSK, Teva See Bigger Issues Than Cash In $235M Award Fight
Attorneys for GlaxoSmithKline and Teva Pharmaceuticals both told a Delaware federal judge on Thursday that far more than money is at stake in post-trial challenges to a $235 million heart drug infringement award won by GSK in June.
-
August 28, 2017
$235M Patent Award Spurs Teva Redo Request, GSK Fees Bid
One month after a Delaware federal jury found Teva Pharmaceuticals willfully infringed a patent tied to the hypertension drug Coreg and handed GlaxoSmithKline a $235 million verdict, Teva on Friday pushed for the court to grant it judgment or a new trial, and GSK asked for enhanced damages and attorney fees.
-
June 21, 2017
GSK Wins $235M Verdict Against Teva In Coreg Patent Fight
Teva Pharmaceuticals USA Inc. should pay GlaxoSmithKline LLC more than $235 million for willfully infringing a patent tied to the hypertension drug Coreg, a Delaware federal jury said.